一年到头了,总是要对过去的这一年做些总结、盘点,那么,在过去的2019年,结直肠癌领域有哪些值得我们记住的治疗进展呢?尤其是那些已经或即将改变我们临床实践的进展。中山大学附属肿瘤医院陈功教授对此进行了详细梳理。
一
1.1 手术相关进展
1.2 新辅助治疗相关进展
在2018年的年终盘点(点击直接跳转)中,我已经详细解读了基于FOWARC研究和中山大学肿瘤医院临床实践数据得出的关于奥沙利铂同步CRT的一些观点:如果治疗的目标是争取最大限度肿瘤退缩(也即追求pCR或TRG)以达到保全括约肌功能,则值得重新审视奥沙利铂的价值,此时应该把奥沙利铂当做标准全身化疗模式而不是放疗增敏剂的模式(每周一次,每次50~60 mg/m2)来使用。
1.3 高危Ⅱ期的术后辅助化疗疗程
1.4 液体活检ctDNA的临床应用
二
晚期疾病篇:Ⅳ期结直肠癌(mCRC)的治疗进展
2.1 mCRC一线姑息治疗新策略:强化治疗能带来更多的生存获益
2.2 末线治疗的精准策略:
2.3 MSS型mCRC的免疫治疗
三
结语
1. Wasmuth HH, Færden AE, Myklebust TÅ, et al. Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg. 2019 Nov; DOI: 10.1002/bjs.11459
2. Larsen SG, Pfeffer F, Kørner H; Norwegian Colorectal Cancer Group. Norwegian moratorium on transanal total mesorectal excision. Br J Surg. 2019 Aug;106(9):1120-1121.
3. Glynne-Jones R, Wyrwicz RL, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (Supple 4): iv22–iv40, 2017 doi:10.1093/annonc/mdx224
4. 中国直肠癌侧方淋巴结转移诊疗专家共识(2019 版);中华胃肠外科杂志2019:22(10):901~912
5. Zhang Z, Sun XC, Liu AW, et al. A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare). J Clin Oncol 37:5s, 2019 (suppl; abstr 3510)
6. Seymour MT, Morton D, et al. FOxTROT: an international randomised controlled trial in 1052 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 37:5s, 2019 (suppl; abstr 3504)
7. Iveson T, Sobrero AF, Yoshino T, et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant oxaliplatin-based therapy (3 vs 6months) for patients with high-risk stage II colorectal cancer. J Clin Oncol 37:5s, 2019 (suppl; abstr 3501)
8. Sobrero AF, Yoshino T, Koehne C. IDEA collaboration for HR stage II. Special session: Adjuvant treatment duration for high stage II colon cancer. ESMO 2019 Congress.
9. Llavero TT, Valiente FG, Gambardella V, et al. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype. ESMO 2019, abstract 522O
10. Taieb J, Taly V, Vernerey D, et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. ESMO 2019, abstract LBA30_PR
11. Sastre J, Vieitez JM, Gomez-Espana A, et al. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with $3 baseline circulating tumor cells. J Clin Oncol 37:5s, 2019 (suppl; abstr 3507)
12. Cremolini C. Antoniotti C, Lonardi S, et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. J Clin Oncol 37:5s, 2019 (suppl; abstr 3508)
13. Geissler M, Knorrenschild JR, Tannapfel A, et al. Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC). J Clin Oncol 37:5s, 2019 (suppl; abstr 3511)
14. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF-mutant metastatic colorectal cancer: Expanded results from a randomized,3-arm,phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). ESMO 2019, abstract LBA 32
15. Sartore-Bianchi A, Martino C, Lonardi S, et al. Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial. ESMO 2019, abstract LBA 35
16. Nakamura Y, Okamoto W, Kato H, et al. Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study. ESMO 2019, abstract 526PD
17. Strickler JH, Zemla T, Ou FS, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial. ESMO 2019, abstract 527PD
18. Chen E, Loree J, Jonker DJ, et al. CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma(rmCRC). J Clin Oncol 37:5s, 2019 (suppl; abstr 3512)
19. Parikh AR, Clark J, Wo J, et al. A Phase 2 study of Ipilimumab and Nivolumab with Radiation in microsatellite stable metastatic colorectal adenocarcinoma. J Clin Oncol 37:5s, 2019 (suppl; abstr 3514)
20. Fukuoka S, Hara H, Takahashi N, et al. Regorafenid plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose –finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol 37:5s, 2019 (suppl; abstr 2522)
END
联系客服